Fig. 3From: Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 monthsTime to first MS relapse after the start of fingolimod treatment (efficacy set, by EDSS score at baseline) EDSS, Expanded Disability Status Scale; MS, multiple sclerosisBack to article page